TransCode Therapeutics Q4 2024 Earnings Deep Losses Reflect PreRevenue Stage ESP Q1 2026 Earnings EPS Surpasses Estimates on Strong Operational Performance EXLS Q1 2026 Earnings EPS Surpasses Estimates by 62 Amid Optimistic Outlook SKYX Q1 2026 Earnings EPS Falls Short of Estimates Amid Ongoing Development NEUP Q1 2026 Earnings Significant EPS Beat Driven by Operational Efficiency FTDR Q1 2026 Earnings EPS Surpasses Estimates with 587 Beat